+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunosuppressant Drugs Market by Function, Drug Class, Route of Administration, End User - Global Forecast 2025-2030- Product Image
Immunosuppressant Drugs Market by Function, Drug Class, Route of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Immunosuppressant Drugs Market by Function, Drug Class, Route of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5014103
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunosuppressant Drugs Market grew from USD 1.11 billion in 2023 to USD 1.18 billion in 2024. It is expected to continue growing at a CAGR of 6.36%, reaching USD 1.71 billion by 2030.

Immunosuppressant drugs are crucial in managing and treating a range of conditions that involve or mimic autoimmune diseases, such as organ transplant rejection, rheumatoid arthritis, and inflammatory bowel disease. Their necessity stems from their ability to suppress immune responses, thereby preventing the body from attacking its tissues or rejecting transplanted organs. The applications of these drugs span across hospitals, specialty clinics, and research institutes with primary end-use in patient care and post-transplant treatment regimens. The market for immunosuppressants is growing, driven by the increasing incidence of autoimmune diseases and the rising number of organ transplants, alongside advancements in biotechnology. However, the market encounters limitations such as stringent regulatory approvals, high costs, and potential side effects of long-term immunosuppression, like infections or malignancies.

Growth factors influencing this market include technological innovations, such as the development of novel drug delivery systems and personalized medicine approaches that tailor treatments to individual patient needs. The aging population and the rising prevalence of chronic diseases also contribute to market expansion. Current opportunities lie in expanding markets in developing regions, where healthcare infrastructure is improving, and awareness of organ transplantation is increasing. Companies should invest in research focusing on biopharmaceutical advancements and collaborations with healthcare providers to optimize supply chains and enhance access. Key recommendations include strategic alliances and partnerships with local firms to penetrate emerging markets and investing in R&D for less toxic, more efficacious drugs with targeted action.

Challenges impacting growth include competition from generic drugs, patent expirations, and the ethical concerns associated with new drug trials. Nonetheless, innovation areas such as gene therapy and the exploration of alternative natural compounds hold promise. The market landscape is competitive but promising, with potential for substantial growth driven by unmet clinical needs and scientific advancements that could herald new categories of treatments, pushing the boundaries of current immunosuppressive therapies.

Understanding Market Dynamics in the Immunosuppressant Drugs Market

The Immunosuppressant Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of autoimmune disease due to changing lifestyles
    • Growing number of organ transplantation procedures for lungs, kidneys, liver, pancreas, and other
    • Improvements in tissue engineering and organ transplantations
  • Market Restraints
    • Complicated regulatory processes
  • Market Opportunities
    • Development of novel drug therapies
    • Recent advances in immuno-oncology and regulatory approvals
  • Market Challenges
    • Complications associated with the personalizing immunosuppressive therapy

Exploring Porter’s Five Forces for the Immunosuppressant Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Immunosuppressant Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Immunosuppressant Drugs Market

External macro-environmental factors deeply influence the performance of the Immunosuppressant Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Immunosuppressant Drugs Market

The Immunosuppressant Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Immunosuppressant Drugs Market

The Immunosuppressant Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Immunosuppressant Drugs Market

The Immunosuppressant Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunosuppressant Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Sebela Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Immunosuppressant Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Function
    • Autoimmune Diseases
      • Localized Autoimmune Disease
      • Systemic Autoimmune Disease
    • Organ Transplant
  • Drug Class
    • Antiproliferative Agent
    • Calcineurin Inhibitor
    • mTOR Inhibitor
    • Steroid
  • Route of Administration
    • Intravenous
    • Oral
  • End User
    • Clinic
    • Hospital
    • Old Age Home
    • Organ Transplant Center
    • Rehabilitation Center
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of autoimmune disease due to changing lifestyles
5.1.1.2. Growing number of organ transplantation procedures for lungs, kidneys, liver, pancreas, and other
5.1.1.3. Improvements in tissue engineering and organ transplantations
5.1.2. Restraints
5.1.2.1. Complicated regulatory processes
5.1.3. Opportunities
5.1.3.1. Development of novel drug therapies
5.1.3.2. Recent advances in immuno-oncology and regulatory approvals
5.1.4. Challenges
5.1.4.1. Complications associated with the personalizing immunosuppressive therapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Immunosuppressant Drugs Market, by Function
6.1. Introduction
6.2. Autoimmune Diseases
6.2.1. Localized Autoimmune Disease
6.2.2. Systemic Autoimmune Disease
6.3. Organ Transplant
7. Immunosuppressant Drugs Market, by Drug Class
7.1. Introduction
7.2. Antiproliferative Agent
7.3. Calcineurin Inhibitor
7.4. mTOR Inhibitor
7.5. Steroid
8. Immunosuppressant Drugs Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Immunosuppressant Drugs Market, by End User
9.1. Introduction
9.2. Clinic
9.3. Hospital
9.4. Old Age Home
9.5. Organ Transplant Center
9.6. Rehabilitation Center
10. Americas Immunosuppressant Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Immunosuppressant Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Immunosuppressant Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. IMMUNOSUPPRESSANT DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ANTIPROLIFERATIVE AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CALCINEURIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY OLD AGE HOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 44. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 45. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 50. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 71. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 72. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 76. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 77. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 87. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 116. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 117. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 133. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 137. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 138. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 142. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 143. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 148. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 152. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 162. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 163. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 177. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 178. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 182. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 183. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 187. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 188. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 207. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 208. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 223. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 237. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Immunosuppressant Drugs Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sebela Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.71 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Immunosuppressants Global Market Report 2024 - Product Image

Immunosuppressants Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Immunosuppressants - Global Strategic Business Report - Product Image

Immunosuppressants - Global Strategic Business Report

  • Report
  • 79 Pages
  • Global
From
Organ Transplant Immunosuppressant Drugs Market by Drug Class (Antibodies, Antiproliferative Agents, Calcineurin Inhibitors), Transplant Type (Heart, Kidney, Liver), Distribution Channel - Forecast 2024-2030 - Product Image

Organ Transplant Immunosuppressant Drugs Market by Drug Class (Antibodies, Antiproliferative Agents, Calcineurin Inhibitors), Transplant Type (Heart, Kidney, Liver), Distribution Channel - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Organ Transplant Immunosuppressant Drugs - Global Strategic Business Report - Product Image

Organ Transplant Immunosuppressant Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Immunomodulators Market by Product (Immunostimulants, Immunosuppressants), Application (HIV, Oncology, Respiratory) - Forecast 2024-2030 - Product Image

Immunomodulators Market by Product (Immunostimulants, Immunosuppressants), Application (HIV, Oncology, Respiratory) - Forecast 2024-2030

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.